Latest therapeutics News | Page 4

Completing First 100 Days Plan
Australian Institute For Infectious Disease One Step Closer
Fast Five With Mark Vidallon
Sustainable innovation: Intellectual property, technology transfer, and global public goods
Certa Therapeutics’ FT011 granted US FDA fast track for systemic sclerosis
Trial shows ‘wonder’ material can be developed safely
Improving screening of new drugs inspires QUT Fulbright Scholar
Capping off a year of generosity
Discovery could lead to new RNA therapeutics for many cancers
Brandon BioCatalyst, in partnership with ANDHealth, selected by Federal Government to deliver $50m Dementia and Cognitive Decline Incubator
Scientists help discover new treatment for many cancers
Optimi Health Congratulates Lykos Therapeutics on FDA Priority Review of New Drug Application And Releases MDMA Production Video
T cells team-up to protect the liver from infection
Vaccine shows promise against CMV, a virus that causes birth defects
First patient receives treatment in Chimeric’s trial of CHM 0201 in AML
The updated WHO Benchmarks for Strengthening Health Emergency Capacities expanded to include public health and social measures (PHSM)
Positive high-level results from Japan Phase III trial of acoramidis in adults with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) showed consistency with global ATTRibute-CM…
Better treatments sooner – Hudson’s new RNAte Platform unveiled
Investing In World-First Tech For Vaccine Development
WHO and MPP announce technology transfer license to enable greater patient access to multiple essential diagnostics
Arovella licences novel CARiNKT cell armouring technology
Structural study points way to better malaria drugs
Chimeric Therapeutics completes placement with shortfall commitments
​​CSIRO launches free program for SMEs innovating in Digital Health and Medical Technology​
Combo treatment improves lung cancer outcomes
Mice without immune cells show no SARS-CoV-2 symptoms
Second WHO global technical consultation on public health and social measures during health emergencies, November 2023
ISU researcher wins innovation challenge to seek RNA drug targets
Strengthening Fiscal Responsibility Rules
Discovery of drug candidate to potentially tackle ER-positive breast cancer
World-first breakthrough in malaria treatment
La Trobe University and AdAlta collaboration delivers world-first breakthrough in malaria treatment
Genetic study aims to unlock new osteoporosis treatments
Hudson Institute welcomes inflammation specialist as new Centre Head
WHO’s Science Council issues report on mRNA vaccine technology
Prescient announces the results of PTX-100 Phase 1b study in T-cell lymphoma patients
EnGeneIC granted FDA “Fast-Track” Designation for Novel Armed Nanocell Drug Conjugate (ANDC) Pancreatic Cancer Therapeutic
Cynata Therapeutics secures approval for Phase 2 trial in Turkey
Microba Life Sciences announces results of successful Phase IBD trial
Korean regulator approves Amplia Therapeutics’ pancreatic cancer trial
Aegros Releases Top-Line Interim Clinical Trial Results of its COVID-19 Hyperimmune
Microba completes stage one screening for its autoimmune disease program
Clairvoyant Surpasses 50 Per Cent Randomization in its Phase 2b Psilocybin Therapy Trial for Alcohol Use Disorder
HKUST Scientists Unveil Promising Target for Alzheimer’s Disease Treatment
Opioid and psychotropic dispensing’s on the decline among Australians living with cystic fibrosis
Cracking the code: researchers unravel how mutant protein drives cancer growth
Oral delivery possibility for silica-based C’Dots
EnGeneIC’s breakthrough Armed Nanocell Drug Conjugate (ANDC) treatment shows promising results in Pancreatic cancer patients who have run out of treatment options